StemCell Therapy

Akcea Therapeutics and Ionis Pharmaceuticals announced the launch of a Phase 3 clinical trial evaluating the safety and efficacy of AKCEA-TTR-LRx (ION-682884) for the treatment of adults with familial amyloid polyneuropathy (FAP).

The global, open-label, randomized NEURO-TTRansform trial (NCT04136184) is expected to start in December. It is recruiting approximately 140 participants ages 18 to 82, diagnosed with stage 1 or 2 FAP, at the Ionis Investigative Site in Boston.

AKCEA-TTR-LRx is a second-generation RNA-targeted therapy in development for the treatment of all forms of transthyretin amyloidosis, including the hereditary (hATTR) and wild-type form of the disease (ATTRwt).

It works by preventing the RNA sequence of the TTR gene, which is defective in people with hATTR, from being translated into a protein. This reduces the buildup of abnormal amyloid deposits that accumulate in several tissues, slowly causing damage and eventually giving rise to symptoms associated with FAP or the other form of hATTR, called familial amyloid cardiomyopathy (FAC). Of note, RNA is the molecule that serves as the template for the production of a protein.

AKCEA-TTR-LRx was originally discovered by Ionis through its proprietary LIgand Conjugated Antisense (LICA) technology platform. It is now being co-developed by Ionis and its affiliate, Akcea.

NEURO-TTRansform will compare the effects of AKCEA-TTR-LRxto the placebo arm of a previous Phase 2/3 trial (NCT01737398), also sponsored by Ionis, that investigated the safety and efficacy of Tegsedi(inotersen) in people with FAP, compared with a placebo.

Once enrolled in NEURO-TTRansform, participants will be randomly assigned to receive subcutaneous (under-the-skin) injections of AKCEA-TTR-LRx every four weeks, or Tegsedi once a week. All study participants also will receive daily supplemental doses of the recommended daily allowance of vitamin A.

Those who are initially assigned to Tegsedi (20 out of the 140 expected to enroll), will cross over to AKCEA-TTR-LRx after 35 weeks.

The studys main goals, which will be assessed at 66 weeks, include analyzing changes from the studys start in the levels of TTR found in the serum, as well as changes in the scores of the modified Neuropathy Impairment Score +7 (mNIS+7) and of the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN).

The mNIS+7 is a measure of neurological impairment that evaluates muscle weakness, sensation, reflexes, nerve conduction, and autonomic function; the Norfolk QoL-DN evaluates the impact of neuropathy on individuals quality of life.

An interim analysis is planned at 35 weeks to assess changes from the studys start in the levels of TTR found in the serum and in mNIS+7 scores.

Patients enrolled in NEURO-TTRansform will be followed for 85 weeks. After completing the study, they will have the option to enroll in an open-label extension study.

The initiation of the TTRransform Phase 3 program represents an expansion of our dedication and commitment to the ATTR community. The NEURO-TTRansform study is the first of two Phase 3 studies that we expect to initiate with AKCEA-TTR-LRx. Our Phase 1 data are encouraging and we are excited about the possibility of delivering a significant advancement for people living with hATTR amyloidosis, Damien McDevitt, PhD, Akceas interim CEO, said in a press release.

In a previous Phase 1 trial (NCT03728634) sponsored by Ionis, it was shown that monthly 90-mg injections of AKCEA-TTR-LRx could lower the levels of transthyretin (TTR), the protein involved in FAP, by up to 94% after 13 weeks of treatment in a group of healthy volunteers.

The Phase 1 data of AKCEA-TTR-LRx are consistent with the clinical profile seen across our other LICA programs, highlighting the potential of LICA-engineered therapies to address both rare and more common diseases, said Brett P. Monia, PhD, chief operating officer of Ionis.

We remain dedicated to advancing this important clinical development program as rapidly as possible and are hopeful about the prospect of bringing a new safe and effective treatment to people living with the devastating symptoms of hATTR amyloidosis in the years ahead, Monia added.

The company also launched the Phase 3 CARDIO-TTRansform clinical trial (NCT04136171), to test AKCEA-TTR-LRx in people with transthyretinmediated amyloid cardiomyopathy (ATTR CM), or FAC. The trial is not yet enrolling.

Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that make up the lining of blood vessels found in the umbilical cord of newborns.

Total Posts: 2

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Read this article:

Phase 3 Trial of Investigative FAP Therapy AKCEA-TTR-LRx Launching - FAP News Today

AMA recently published a detailed study of over 180+ pages in its repository on Neuropathy Pain Treatment market covering interesting aspects of market with supporting development scenario till 2025. The study provides market size break-up by revenue and volume* for emerging countries and important business segments along with commentary on trending factors, growth drivers. Profiled players in study from the coverage used under bottom-up approach are Pfizer [United States], Depomed [United States], Eli Lilly [United States], Endo [Ireland], Grnenthal Group [Germany], Arbor Pharmaceuticals [United States], Astellas Pharma Inc. [Japan], Biogen Inc. [United States], Baxter Healthcare Corporation [United States], Sanofi S.A [France], Abbott Laboratories [United States], AstraZeneca [United Kingdom], Johnson & Johnson Services Inc. [United States], GlaxoSmithKline plc [United Kingdom], Depomed Inc. [United States].

Neuropathy pain treatment involves cure of pain associated with somatosensory nervous system. As of 2018 data, 18% of Canadian population, 7% of French and over 4% of United Kingdom population experience pain of neuropathic origin. With growing geriatric population across the world, the number of neuropathic pain causing diseases will increase significantly, thus, giving pain treatment services offering companies an opportunity to explore in untapped market.

Next step one should take to boost sales? Track latest strategic steps and current scenario analysis of the market @ https://www.advancemarketanalytics.com/sample-report/32655-global-neuropathy-pain-treatment-market

Market Segmentation

by Type (Peripheral Neuropathy, Entrapment Neuropathy, Post Traumatic Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Phantom Limb Pain, Others), Indication Type (Diabetic Neuropathy, Trigeminal Neuralgia, Post-herpetic Neuralgia, Chemotherapy-induced Peripheral Neuropathy, Others.), Treatment (Medication, Multimodal Therapy), Distribution Channels (Pharmacies, Retail Pharmacies, Online Pharmacies), End-user (Hospitals, Clinics, Research Organizations), Diagnosis (Imaging, Blood Tests)

Make an enquiry before buying this Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/32655-global-neuropathy-pain-treatment-market

Whats Trending in Market:

Increasing Demand of Generic Drugs

Emergence of Innovative Pain Treatment Methods Such as Use of Electrical Stimulation Devices, Stem Cell Procedures and Others

Growth Drivers: Rising Geriatrics Population Across the World

Growing Number of Cancer and Diabetes Cases

Restraints: High Cost of Neuropathy Pain Treatment

Lack of Health Infrastructure and Budgets in Emerging Countries

View Detailed Table of Content @ https://www.advancemarketanalytics.com/reports/32655-global-neuropathy-pain-treatment-market

Country level Break-up includes:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Try a limited scope research document specific to Country or Regional matching your objective.

GET FULL COPY OF United States Neuropathy Pain Treatment market study @ USD 2000

And, Europe Neuropathy Pain Treatment market study @ USD 2500

Strategic Points Covered in Table of Content of Global Neuropathy Pain Treatment Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Neuropathy Pain Treatment market

Chapter 2: Exclusive Summary the basic information of the Neuropathy Pain Treatment Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Neuropathy Pain Treatment

Chapter 4: Presenting the Neuropathy Pain Treatment Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region 2013-2018

Chapter 6: Evaluating the leading manufacturers of the Neuropathy Pain Treatment market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Buy this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=32655

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:

CRAIG FRANCIS (PR & Marketing Manager)

[emailprotected]

Ph: +1 (206) 317 1218

Go here to see the original:

Neuropathy Pain Treatment Market Set For Rapid Growth and Trend | Statistics Analysis and Opportunities 2024 - News Description

The Global Neuropathy Pain Treatment Market is the increasing incidence of neuropathic pain caused by damage or

disease affecting the somatosensory nervous system. Growing awareness among patients and increase in the demand for generic drugs boost the market growth. However, severe side effects of opioids and steroids and rising costs of branded drugs might hamper the market growth

Buy one-Get one: https://www.orianresearch.com/checkout/956157

[Buy this report and get another report of the same price for free. offer for limited period only].

Based on type, the market is divided into:

Based on application, the market is divided into:

Moreover, the market is classified based on regions and countries as follows:

For More Info, Get Sample Report Here @ https://www.orianresearch.com/request-sample/956157

Key Market Players:

Key Benefits of the Report:

Target Audience:

GET Flat 40% Discount https://www.orianresearch.com/discount/956157

[Avail flat 40% discount on this report. offer for limited period only]

Table of Contents

Customization Service of the Report:

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email: [emailprotected]

Website: http://www.orianresearch.com

See the original post:

Global Neuropathy Pain Treatment Profiling Industry 2019 Market Share, Regional Analysis, Growth Insights, Leading Companies, End Users and Forecast...

Rising Prevalence of Cancer Worldwide to Promote Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth

A painful dysfunction of the somatosensory nervous system in the body is called chemotherapy-induced peripheral neuropathy or CIPN. It is estimated that chemotherapy-induced peripheral neuropathy affects an estimate of 68.0% patients who undergo within their first month of diagnosis, among which 30% patients are affected on a chronic basis. The rising prevalence of chronic diseases is promoting the growth of Chemotherapy Induced Peripheral Neuropathy Treatment market. According to Fortune Business Insights, the market for Chemotherapy Induced Peripheral Neuropathy Treatment is anticipated to rise exponentially with increasing prevalence of diabetes worldwide.

Browse Complete Report [emailprotected] https://www.fortunebusinessinsights.com/industry-reports/chemotherapy-induced-peripheral-neuropathy-treatment-market-101218

Rising Prevalence of Cancer to Help Generate High Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenues

The increasing prevalence of chronic diseases such as diabetes and cancer are the major factors promoting the Chemotherapy Induced Peripheral Neuropathy Treatment market. The surge in adoption of chemotherapy is significantly helping to increase the prevalence of peripheral neuropathy. Additionally, lack of proper guidelines about chemotherapy heightens the chance of additional incidence of peripheral neuropathy. This is expected to bode well for generating greater percentages of the global Chemotherapy Induced Peripheral Neuropathy Treatment market share.

However, the market may face certain challenges in terms of the lack of awareness about symptoms of chemotherapy-induced peripheral diagnosis, especially in developing nations. Such challenges may hamper the global Chemotherapy Induced Peripheral Neuropathy Treatment market growth in the forecast period.

Get PDF Brochure of this [emailprotected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/chemotherapy-induced-peripheral-neuropathy-treatment-market-101218

Some of the companies operating in the global Chemotherapy Induced Peripheral Neuropathy Treatment market include:

Improving Healthcare Infrastructure and Medical Facilities of Developing Nations to Help Asia Pacific Market Grow Significantly

According to the Center for Diseases Control and Prevention (CDC), ABOUT 1,633,390 new cancer cases were reported in the U.S. in 2015, among which, an estimated 595,919 people died of cancer. As per the geographical categorization, North America is currently holding a significant share in the global Chemotherapy Induced Peripheral Neuropathy Treatment market and is anticipated to continue doing the same in the forecast period as well. This is attributable to the rising prevalence of cancer which is further propelling the demand for chemotherapy treatment by patients and their family members.

On the other side, the global Chemotherapy Induced Peripheral Neuropathy Treatment market in Asia Pacific and Europe will also witness remarkable growth rate during the forecast period owing to improving healthcare infrastructure and medical facilities, especially in the developing nations.

Strategic Partnerships to Help Market Players Gain Strong Foothold in Market

As per the report, the global Chemotherapy Induced Peripheral Neuropathy Treatment market highlights some of the major market shareholders significantly driving the market. These companies are mentioned below

Manufactures continue to focus on new product launches and merger and acquisition strategies to increase their customer base and broaden product portfolio. These manufacturers produce new therapeutic methods to maintain a strong foothold in the market. Some of the recent development made by companies are mentioned below

More Trending Topics From Fortune Business [emailprotected]

U.S. Biosimilars Market 2019 Global Technology, Consumption, Segmentation, Growth, Development, Trends and forecasts to 2026

Mass Spectrometer Market Size Overview by Share, Growth Factor, Industry Trends, and Analysis to 2026

About Us

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Chemotherapy Induced Peripheral Neuropathy Treatment Market to Generate Higher Revenues by Entering into Strategic Collaborations says Fortune Business Insights

The rest is here:

Chemotherapy Induced Peripheral Neuropathy Treatment Market to Generate Higher Revenues by Entering into Strategic Collaborations says Fortune...

Diabetic Peripheral NeuropathyMarket

Diabetic PeripheralNeuropathy-Epidemiology Forecasting Intelligence report provides acomprehensive analysis of the Diabetic Peripheral Neuropathy epidemiology,providing the historical, current, and forecasted data for the United States,European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) andJapan during the period from 2018-2028.

Our epidemiology services include:

Incidence andprevalence Diagnosis rate, treatment rate and mortality patterns Epidemiology-based forecasting and disease trends Size of different patient segments in a disease area Population based: disease occurrence, co-morbidities and treatment patterns Geographic Regional Ethnic differences

Along with the epidemiological data, the reportalso includes:

Disease overview,causes, symptoms, classification, risk factor, pathophysiology, diagnosis andtreatment Patient treatment journey Treatment algorithm and guidelines Assesses the disease risk and burden Highlights the unmet needs Market driver and barrier Growth opportunities and market trend analysis

Methodology

This report isbuilt using data and information sourced from proprietary databases, primaryand secondary research and in-house Epidemiology Forecast model analysis by ateam of industry experts. To generate accurate patient population estimates, utilizes a combination ofseveral world class sources that deliver the most up to date information frompatient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have beenidentified in the report.

Note:

Systematic review ofthe epidemiological literature is also provided for full transparency intoresearch and methods. This report can be delivered to the clients within 4-5business days.

Request customize:-

If you wish to find more details ofthe report or want a CustomizationPlease contacts us. You can get adetailed of the entire research here.

Ozone Market Reports is committed towards delivering intensiveresearch based analysis reports, enabling clients to easily make fact-baseddecisions. We also have with us the facility of our innovatively designed anddeveloped data processing and analysis division.

Ozone Market Reports is a research-based consulting firmspecializing in getting research inputs and using them appropriately in themarketing planning process. In saying this, we are trying to convey that wealways attempt to interpret the research data from the viewpoint ofrecommending action priorities both short-term and long-term. To this end, wehave put together a team that understands not only research techniques, butalso branding concepts in depth.We believe our people are our clientsbiggest assetshence we do our best to recruit multi-skilled individuals,and then give them an environment where they can think and ideate freely.

We offer various services for our clients to help them choosewhats most relevant and best for them required for their business.

Contact Us:

Name: Steven Samuel

Email info@ozonemarketreports.com

Phone +91 9370882135

Website: https://www.ozonemarketreports.com/

Post Views: 70

Read the original post:

Diabetic Peripheral Neuropathy Market - Growth, Future Prospects, and Competitive Analysis 2028 - Market Tribunal

For patients with diabetes, cardiovascular disease should be a top priority.

Nathan D. Wong, PhD, director of the Heart Disease Prevention Program at the University of California, Irvine, is a co-author of the Heart Disease and Diabetes chapter in the NIDDK publication Diabetes in America, 3rd Edition. Here he talks about the importance of broadening the clinical focus of diabetes care from hemoglobin A1C to also include other risk factors for cardiovascular disease common in patients with diabetes.

Q: Why is it so important to talk about heart disease with patients who have diabetes?

A:More than two-thirds of patients with diabetes will die of cardiovascular-related illnesses such as coronary heart disease, stroke, heart failure, and peripheral arterial disease. For women with diabetes, the risks for different forms of cardiovascular disease are three to seven times greater compared with women who do not have diabetes. For men with diabetes, the risk is two to three times greater.

We are doing a poor job of managing heart disease in people with diabetes in this country and throughout the world, despite many advances in therapies over the past 30 years. We still have a very small percentage of people with diabetesfewer than one in fivewho meet appropriate targets for hemoglobin A1C, blood pressure, and LDL cholesterol; even fewer additionally meet the recommendations for physical activity, a healthy diet, nonsmoking status, and body mass index.

Many of these factors have an impact on risk for certain microvascular complications associated with diabetes such asretinopathy, nephropathy, and neuropathy. But these factors also affect risk for macrovascular complications such as heart disease and stroke.

Q: How does cardiovascular risk differ for type 1 and type 2 diabetes?

A:When people are diagnosed with type 2 diabetes, they often already have hypertension and dyslipidemia. For people with type 1 diabetes, the diagnosis generally comes when theyre much younger, so they arent yet at significant cardiovascular risk. Theres a true opportunity to help prevent them from developing cardiovascular risks in the first place, rather than trying to catch up with these factors after theyve developed and are more difficult to control.

Q: What are the benefits of keeping all the cardiovascular risk factors at target levels?

A: The Steno 2 clinical trial found a 53% risk reduction in cardiovascular outcomes for people with type 2 diabetes who were intensively treated for risk factors, compared with participants in the control group. In a follow-up paper, the researchers reported on mortality rates after 13 years. They found it was significantly lower for the intensively treated group. Just 30% had died, compared with 50% of the conventionally treated group.

In an observational study, we pooled data on people with diabetes from three different clinical trials to show an approximately 60% lower risk for developing coronary heart disease or cardiovascular disease in people with diabetes who were at target levels for LDL cholesterol, blood pressure, and hemoglobin A1C. This suggests we can possibly reduce the risk of future heart attacks or strokes by more than half, if we ensure that these factors are controlled.

Q: What does this mean for diabetes care?

A:We still have a lot of work to do to get the word out that diabetes is really a cardiovascular condition. Most people with diabetes are not dying from retinopathy or neuropathy; they are dying from cardiovascular disease. This is not to trivialize the microvascular complications. Obviously, neuropathy or retinopathy can significantly affect quality of life. But in terms of what a person with diabetes eventually will die of, its cardiovascular disease. Patients and their health care providers really have to better understand that controlling diabetes is much more than controlling blood sugar.

Certainly, managing glucose is critical to prevent microvascular complications, in particular. There is strong epidemiologic data that adverse cardiovascular outcomes are greater in people with higher levels of hemoglobin A1C, but the evidence is less striking for improving cardiovascular outcomes from glucose control alone. And in fact, the ACCORD trialactually showed increased cardiovascular mortality to occur when targets were set too aggressively for hemoglobin A1C.

Q: How can the message on cardiovascular risk factors reach more health care professionals?

A:I think theres tremendous opportunity to advance professional education to help improve cardiovascular outcomes in people with diabetes. And this, of course, can be accomplished with lifestyle changes. But few people with diabetes see a dietician and/or exercise physiologist as frequently as they should to help them with theirdiabetes self-management. These allied health care providers are not traditionally part of the health care team as much as they should be, because reimbursement is not always available for their services. Physicians need to know that these resources exist, and that they can also prescribe lifestyle improvements such as walking or eating more vegetables.

At professional meetings, I've asked for a raise of hands: How many of you physicians have heard of the American Medical Association? Virtually all of them have. Then I ask, How many of you have heard of theAcademy of Nutrition and Dietetics? Very few have, yet this is a very powerful group. Specifically, the Academys Sports, Cardiovascular and Wellness Nutrition dietetic practice group includes close to 10,000 people around the country. The American College of Sports Medicine includes exercise physiologists. But there's a disconnect. We need to help physicians know that these other providers, who are key to patients success in managing their diabetes and cardiovascular risks, exist.

Q: How can cardiologists contribute to better care for patients with diabetes?

A:The American College of Cardiology advocates for cardiologists to learn more about how to manage diabetes. This is largely fueled by the fact that we now have newer medications that are shown to reduce cardiovascular events in people with diabetes. These drugs are not the most powerful A1C-lowering agents, but theyre the only agents shown to have benefits in terms of cardiovascular outcomes. The sodium-glucose cotransporter-2 (SGLT2) inhibitors, in particular, have the dramatic effect of reducing heart failure-related hospital stays by more than 30%. Equally exciting are the glucagon-like peptide-1 (GLP-1) receptor agonists, which seem to have more of an anti-atherosclerotic effect.

Both of these therapies have been incorporated into several guidelines. The American College of Cardiology, the American Association of Clinical Endocrinologists, the American Diabetes Association, and the American Heart Association recommend these therapies specifically for people with pre-existing diabetes and cardiovascular disease.

But its mainly the specialty community that has started to use these therapies. We need to increase efforts to communicate the value and the indications of these therapies among primary care providers, too.

Q: What advice do you have for health care professionals so that they can better help their patients with diabetes manage the cardiovascular risk factors?

A:Providers and patients with diabetes alike need to understand that cardiovascular disease should be their main concern. It takes a concerted approach to manage all the relevant risk factors to significantly improve outcomes. Were talking about a multidisciplinary cardio-diabetes care team that includes lifestyle specialistsdieticians and physical activity expertsas well as other appropriate specialists, including the endocrinologist and the cardiologist, and, in many cases, the primary care provider at the center of the patients care.

Health care professionals also need to motivate patients to take greater charge in their health care.Shared decision-making is very important in starting new therapies and managing lifestyle changes.

What has been your experience addressing cardiovascular risk in your patients with diabetes? Tell us below in the comments.

Follow this link:

Addressing Cardiovascular Risk Factors in People with Diabetes - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

The Inherited Neuropathy Consortium led by University of Iowa neurologist Michael Shy has received a grant renewal to continue studying inherited neuropathies.

The Carver College of Medicine is pictured on Wednesday, April 4, 2018.

Gaoyuan Pan

The Carver College of Medicine is pictured on Wednesday, April 4, 2018.

Gaoyuan Pan

Gaoyuan Pan

The Carver College of Medicine is pictured on Wednesday, April 4, 2018.

As clinical research of medical technology advances, so will the understanding of genetic neurological diseases. The National Institute of Health has renewed the University of Iowas grant to study inherited neuropathic diseases.

The Inherited Neuropathy Consortium, located in the UI Carver College of Medicine, recently received a five-year $7.2 million grant renewal to continue researching inherited peripheral neuropathies in the hope of finding a cure for related diseases.

Peripheral neuropathies are disorders affecting the nerves that spread from someones back to their hands and feet, which can cause weakness and balance problems, UI neurologist Michael Shy said. Although these disorders have many causes, he said, a common cause is a genetic mutation that can disrupt the nerves.

Shy said the diseases are referred to as Charcot-Marie-Tooth type 1 or type 2, depending on which part of the nerve the disease affects. These diseases are fairly common and affect one in 2,500 people, he added.

Up until 1990, there were no known genetic causes for any of these, although it was known that the diseases could be genetic, Shy said. Now theres mutations in over 100 different genes that can cause these disorders.

The consortium works with other institutions around the world to determine how these diseases change over time, identify other genetic causes of Charcot-Marie-Tooth, and train physicians to study and treat the diseases, Shy said.

With the grant renewal, the consortium will continue its study of how Charcot-Marie-Tooth changes over time through using different outcome measurements they have developed and new instruments allowing them to measure outcomes in infants, Shy said.

RELATED: UI doctors prepare to study obscure leading cause of death in refractory epilepsy

The grant will also allow researchers to continue to identify and study biomarkers in patients blood that are common for Charcot-Marie-Tooth, he said.

Even though clinical trials have been developed to treat the diseases, there is no cure, Shy said. The clinic emphasizes genetic counseling to help people understand their condition and the potential it has to pass on to other generations, he said.

Counselors meet with families to discuss genetic testing options, provide an understanding of what their insurance will cover, and an understanding of the various lab testing they will receive, said Shawna Feely, genetic counselor and clinic coordinator.

Feely is the consortiums project manager and oversees the 20 sites involved. She helps research teams navigate protocols, understand the testing, and create uniformity in the way clinical trials are conducted.

RELATED: University of Iowa receives grant to improve statewide-maternal-health

Any time youre giving a genetic diagnosis, there can be an emotional element to the person or family in terms of family dynamics or feeling guilt that someones passed a genetic disease on, and so genetic counselors part of the counseling part is to help families cope, Feely said.

Genetic counselor Tiffany Grider said in an email to The Daily Iowanthat a common question from patients is whether or not their child will have the same condition, and whether theres a treatment for it.

Researchers like Dr. Shy have spent decades learning the exact biological mechanism for how these diseases happen, Grider said.

With the developing research and the grant, the future of the clinic and genetic testing will be in the hands of the next generation, Shy said.

Its this next generation of scientists who are going to take this to the clinic, so these are going to become treatable diseases, Shy said. And we need that generation to be well-trained to be able to develop [treatments].

Read the original:

UI-led neuropathy consortium receives grant renewal from National Institute of Health - UI The Daily Iowan

HOUSTON Deborah Brancato has worked as a flight attendant for 25 years, but after undergoing chemotherapy to treat breast cancer, she developed neuropathy. The pain in her feet was so bad she was not able to stand for long periods of time and couldn't wear the required closed-toed shoes that were part of her uniform.

Brancato needed to find a solution to treat the pain she experienced from neuropathy. She found help at Advanced Nerve and Health Center, where patients of Dr. Bao Thai are seeing amazing results. Dr. Thai has developed a non-invasive, pain free treatment that helps the body repair nerves without surgery or medication.

Dr. Thai is a pioneer in this field, and has studied all over Europe and Asia exploring technologies and processes. He conducted his own research and found that the body wants to heal the nerve, and over time it will heal.

The Advanced Nerve and Health Center has a limited time offer for Great Day Houston viewers. For $39, the first 17 callers will get an in-office consultation, a copy of Dr. Thai's "Healthy Diet to Heal Nerve Pain" book, and a diagnostic nerve test to see if they can help. This is a $399 value.

Call Advanced Nerve and Health Center now at 832-626-1260.

Advanced Nerve and Health Center is located at 8558 Katy Freeway, Suite 116, Houston, TX 77024.

For more information, log on to NerveAndHealth.com.

This content is sponsored by: Advanced Nerve and Health Center.

Here is the original post:

Advanced Nerve & Health Center helps breast cancer survivor reverse her neuropathy - KHOU.com

In 2018, the market size of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Stroke Prevention in Atrial Fibrillation (SPAF) Treatment .

This report studies the global market size of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @ https://www.researchmoz.us/enquiry.php?type=S&repid=2525974&source=atm

This study presents the Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment history breakdown data from 2014 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2018.

In global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market, the following companies are covered:

Boehringer IngelheimBayerJohnson & JohnsonBristol-Myers SquibbPfizerDaiichi-SankyoGilead

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeOral Direct Thrombin InhibitorsOral Direct Factor Xa Inhibitors

Segment by ApplicationHospitalsClinicsAmbulatory Surgical Centers

Make An EnquiryAbout This Report @ https://www.researchmoz.us/enquiry.php?type=E&repid=2525974&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment , with price, sales, revenue and global market share of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment in 2017 and 2018.

Chapter 3, the Stroke Prevention in Atrial Fibrillation (SPAF) Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Stroke Prevention in Atrial Fibrillation (SPAF) Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2018.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2525974&licType=S&source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2018.

Chapter 12, Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market forecast, by regions, type and application, with sales and revenue, from 2018 to 2024.

Chapter 13, 14 and 15, to describe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Read the rest here:

Cardiac Autonomic Neuropathy Treatment Market expected to Witness a Sustainable Growth over 2017 2025 - Health News Office

TheDiabetic Neuropathy Market is a professional and in depth market reportthat focuses on primary and secondary drivers, possible sales volume, market share, leading segments, market size and geographical analysis of the market. It shows that the increase in market value is generally attributed to the increasing growth of the applicable industries and the subsequent increase in demand for applications. The Diabetic Neuropathy market analysis examines the different segments that are relied on to witness the fastest growth in the approximate forecast frame. The competitive landscape section of the Diabetic Neuropathy report provides a clear insight into the market share analysis of major industry players.

Diabetic Neuropathy Market: Scope of the Report :

This report provides an all-inclusive environment of the analysis for the Diabetic Neuropathy Market. The market estimates provided in the report are the result of in-depth secondary research, in-house expert reviews, and primary interviews. These market estimates have been considered by studying the impact of various social, political and economic factors along with the current market dynamics affecting the Diabetic Neuropathy Market development. In addition to the description of the market, which includes market dynamics, the chapter includes Porters Five Forces analysis which explains the five forces; namely buyers bargaining power, suppliers bargaining power, the threat of new entrants, threat of substitutes, and degree of competition in the Diabetic Neuropathy Market. The report also focuses on the competitive landscape of the Diabetic Neuropathy Market.

For Better Understanding Go With this Free Sample Report Enabled with Respective Tables and Figures:https://marketresearch.biz/report/diabetic-neuropathy-market/request-sample

Diabetic Neuropathy Market: Competitive Landscape

The market analysis entails a section solely dedicated to major players in the Diabetic Neuropathy Market wherein our analysts provide an insight into the financial statements of all the major players, along with its key developments, product benchmarking and SWOT analysis. The Company Profile section also comprises a business overview and financial information. The companies that are provided in this section can be customized according to the clients requirements.

There are some key players Pfizer Inc, Eli Lilly and Company, Actavis Pharma Inc, Cephalon Inc, Meda Pharma GmbH, GlaxoSmithKline plc, NeuroMetrix Inc, Johnson & Johnson Inc, Boehringer Ingelheim GmbH, Astellas Pharma Inc.

Diabetic Neuropathy Market Segments:

Segmentation on the basis of disorder type:

Peripheral neuropathyAutonomic neuropathyProximal neuropathyFocal neuropathySegmentation on the basis of treatment:

RadiotherapyPhysiotherapy

Key Questions Answered by This Report:

How did the market evolve and what is the market status in 2019?

What are the drivers and restraints of the Market?

What are the opportunities for growth within the market and where do the major threats lie?

How will each submarket segment grow in the near future and how much market value will each segment generate for 2019 2028?

How the political, economic, social, and technology factors influence the submarkets and regional market?

How will individual leading Worldwide markets perform over the forecast period, and what are their drivers and restraints?

What have been the major developments of the leading Worldwide markets over recent years, leading to their current market status?

How will the market shares of the regional and leading Worldwide markets evolve by 2019 2028, and which geographical region will lead in 2019 2028?

Who are the key players within the market, and what are their strategies over the forecast period?

Share Your Questions Here For More Details On this Report or Customizations As Per Your Need:https://marketresearch.biz/report/diabetic-neuropathy-market/#request-for-customization

In more detail, the chapters of this report contain the following topics:

Chapter 1 It consists of research objective and assumption, research objectives of the report

Chapter 2 Introduces the market; discusses the different segmentations of the market; summaries the report

Chapter 3 Includes market drivers, restraint, opportunity, and trends contributing to the growth of the market. The dynamic section of the report also includes DR Impact Analysis, Opportunity Orbit, PEST Analysis, and Porters Five Analysis.

Chapter 4 Studies the global market, providing market shares and sales figures. The chapter also analyses market forecasts, factors enabling growth, and the future of the market, covering the period 2018-2029. Furthermore, it provides in-depth detailed analyses and forecasts of the submarkets.

Chapter 5 provides an in-depth and thorough analysis of the regional and Worldwide markets. The chapter continues by supplying market forecasts, details on growing regions, factors enabling the growth, drivers, and restraints on a Worldwide basis, developments over 2015 and their influence over the forecast period, and future market predictions, covering the period 2018-2029.

Chapter 6 Identifies, discusses and analyzes the leading players in the market, as well as innovative, growing companies that will impact the future of the industry.

Chapter 7 Explains the research methodology the company follows to create, enriched insights to clients from millions of data points.

Inquire/Speak To Expert for Further Detailed Information About Diabetic Neuropathy Report:https://marketresearch.biz/report/diabetic-neuropathy-market/#inquiry

Excerpt from:

PDF Report : Diabetic Neuropathy Market 2019 || Comprehensive Analysis of the market with Competitive Landscape and Forecasts To 2028 - Tech News...

October is Breast Cancer Awareness Month. In some ways, the month is a celebration of the many advances made toward diagnosing and treating breast cancer at its very earliest stages. With these earlier identifications come the expectations for more favorable treatment and survival outcomes.

That said, when a cancer diagnosis is delivered, the individual receiving it often hears nothing but I have cancer. Words like these can be overwhelming. It begins a search to gather and develop the most competent team to lead you through this journey.

There are many options when considering breast cancer surgery. Those are for you and your surgical team to examine. Perhaps you have chosen to pursue a lumpectomy or a mastectomy. These procedures might include lymph nodes being removed in the axilla (the armpit), to discover if a cancer has spread elsewhere.

But what happens after a tumor has been removed? Surgical intervention can deliver a whole new set of concerns including:

n Tissue adhesions that can lead to postural changes

n Impaired shoulder function

n Pain and subsequent movement compensations

n Seromas

n Hematomas

n Serratus anterior weakness

n Axillary web syndrome/cording (scarring or connective tissue under the arm that can limit range of motion)

Lymphedema is also a common side effect following breast cancer surgery. It occurs after the lymph nodes have been removed or damaged, impairing normal lymphatic flow in the arm, which causes the arm to swell.

Your plan of care might also include radiation or chemotherapy. If radiation is part of your treatment, there can be temporary tissue adhesions; reduced shoulder and trunk range of motion; inflammatory edema (swelling caused by excess fluid); and pain. You may also experience permanent changes called radiation fibrosis, which is scar tissue that can occur in the breast and chest wall.

If your oncology team decides chemotherapy is warranted, challenges from the treatment can include pain; fatigue; poor tolerance to activity; neuropathy; weakness; and an increased risk of cardiovascular disease.

Regardless of your breast cancer treatment approach, every survivors plan for recovery should include treatment for whatever physical changes you may experience. It is imperative to see a physical therapist and certified lymphedema therapist early on to ensure the best results.

A therapist trained in breast cancer rehabilitation can work with you to:

n Address shoulder, complex movement, and soft tissue disorders

n Improve your comfort and function during and following breast reconstruction

n Address effects of radiation

n Reduce fatigue and weakness

n Develop an individualized home exercise program

St. Peters Health Partners Patient Therapies has a variety of outpatient physical therapists at locations throughout the Capital District, accepting all insurances and providing quality one-on-one treatment. Our staff works closely with your oncology and/or primary care team to help decrease pain, improve flexibility, and reduce effects of scar tissue adhesions/radiation fibrosis.

If you are seeking treatment for lymphedema, our therapists have received specialized training in manual lymph drainage and compression bandaging. We have the longest operating lymphedema management program in the Capital District.

For information, call 518-268-5749 or visit us at http://www.sphp.com/patient-therapies.

See more here:

Surviving breast cancer what comes next? - Hudson Valley 360

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global diabetic neuropathy drugs market since 2016 and the market is poised to grow by USD 866.72 million during 2019-2023, progressing at a CAGR of about 6% during the forecast period. Request Free Sample Pages

Read the 135-page research report with TOC on "Diabetic Neuropathy Drugs Market Analysis Report by Mechanism of action (calcium channel alpha-2-delta ligand, SNRIs and TCAs, and others), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 - 2023."

The market is driven by the approval of new drugs and the presence of a strong drug pipeline. In addition, the development of novel biologics to treat diabetic neuropathy is anticipated to further boost the growth of the diabetic neuropathy drugs market.

Market vendors are increasingly focusing on the development of disease-modifying drugs to treat diabetic neuropathy due to its growing prevalence. The market is witnessing an increase in the number of approvals of drugs such as LYRICA CR extended-release tablets. These drugs are used to manage neuropathic pain associated with diabetic peripheral neuropathy. In addition, there are several drugs that are in the last-stages of the pipeline. VM202 is an investigational therapy that is currently in Phase III clinical trials. Thus, approval of such new drugs and the presence of a strong drug pipeline is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for FREE.

View market snapshot before purchasing

Major Five Diabetic Neuropathy Drugs Market Companies:

Pfizer Inc.

Pfizer Inc. is headquartered in the US and owns and operates businesses under various segments such as innovative health and essential health. The company offers LYRICA and NEURONTIN. LYRICA is used to treat diabetic nerve pain.

Novartis AG

Novartis AG is headquartered in Switzerland and manufactures products through several business segments such as innovative medicines, sandoz, and alcon. The company offers Tegretol, which is an anticonvulsant medication used in the treatment of neuropathic pain.

Johnson & Johnson Services, Inc.

Johnson & Johnson Services, Inc. is headquartered in the US and has business operations under various segments, namely pharmaceutical, medical devices, and consumer. The company offers NUCYNTA, which is an opioid analgesic used to treat diabetic neuropathy pain.

Eli Lilly and Company

Eli Lilly and Company is headquartered in the US and offers products through business segments such as human pharmaceutical products and animal health products. The company offers CYMBALTA, which is used to treat neuropathic pain.

DAIICHI SANKYO COMPANY, LIMITED

DAIICHI SANKYO COMPANY, LIMITED is headquartered in Japan and offers products through business segments such as innovative pharmaceuticals business and generic business. The company offers Tarlige, which is used to treat peripheral neuropathic pain.

Register for a free trial today and gain instant access to 10,000+ market research reports. Technavio's SUBSCRIPTION platform

Diabetic Neuropathy Drugs Mechanism of Action Outlook (Revenue, USD Million, 2019 - 2023)

Diabetic Neuropathy Drugs Regional Outlook (Revenue, USD Million, 2019 - 2023)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care are:

Pericarditis Drugs Market Global Pericarditis Drugs Market by product (NSAIDs, colchicine, and others) and geography (Asia, Europe, North America, and ROW).

Blepharitis Drugs Market Global Blepharitis Drugs Market by product (steroids and antibiotics) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Continued here:

Diabetic Neuropathy Drugs Market 2019-2023 | Evolving Opportunities with Pfizer Inc. and Novartis AG | Technavio - Business Wire

Anxiety is a common response to an increasingly demanding society and work culture. We are surrounded by physical and mental stressors that may impact the body in ways that mirror peripheral neuropathy symptoms.

For caregivers and patients suffering from familial amyloid polyneuropathy, it is important to be aware of how stress affects peripheral neuropathy symptoms and to distinguish the differences in bodily reactions to these stressors.

The symptoms of stress may be similar to those of peripheral neuropathy. That includes the constricting of blood vessels due to hyperventilation and seemingly hyperactive nerve activity.

Patients who are prone to anxiety attacks must be aware of how their hands, feet, and arms are feeling. The constriction of blood cells caused by hyperventilation may increase tingling and burning sensations in the peripheral nerves. Patients and caregivers should be aware of how reduced blood flow due to hyperventilation may impact existing peripheral neuropathy symptoms.

Anxiety may also cause increased nerve reactions in the body. The increase in nerve firings may cause cramps and symptoms similar to nerve damage. As these symptoms may feel similar to those caused by peripheral neuropathy, caregivers and patients must be diligent in having both topical treatments and stress-relieving exercises readily available.

Breathing exercises may help patients relax during times of increased stress. During hyperventilation, patients should breathe in deeply, holding each breath for a few seconds and then slowly breathing out for seven to 10 seconds. This exercise helps patients relax their bodies and may help to reduce the effects of hyperventilation caused by anxiety.

Spending time with loved ones helps patients distract themselves from stressors that may cause anxiety. Being around people whose company a patient enjoys may help increase feelings of happiness. Activities may include spending time with children, traveling with family, or spending holidays together.

My mother-in-laws preferred method of battling anxiety and depression is by spending time with her loved ones. She is rooted in her family. The time spent with them provides her with a sense of purpose and a distraction from her bodily pains. They are her support center when she needs it.

Massage therapy may help patients relax their bodies and reduce the impact of peripheral neuropathy symptoms. Relaxing the body is an effective way to mitigate the effects of anxiety. When pursuing massage therapy, caregivers need to understand their patients thresholds for touch. Applied pressure may cause increased pain and essentially negate the desired outcome for massage therapy.

Massage therapy may include self-administered massages, professional massages, and foot massages. The ultimate goal for patients pursuing massage therapy for anxiety is to relax the body while providing a mental distraction that reduces the symptoms.

What are some ways that you reduce stress or anxiety? Please share in the comments below.

***

Note: FAP News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of FAP News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to familial amyloid polyneuropathy.

Sorry! The Author has not filled his profile.

See the original post:

How Caregivers and Patients Can Manage Bodily Responses to Stress - FAP News Today

LOS ANGELES--(BUSINESS WIRE)--There has recently been an increase in need for Pain Medicine Experts to perform Independent Medical Evaluations (IMEs) and act as Expert Witnesses in the San Francisco Bay Area. To fill the demand, California Medical Evaluators (CME) has added several pain medicine expert witnesses to its network of board-certified and highly competent doctors.

A Pain Medicine IME is performed by a board-certified pain medicine expert who uses his/her expertise to evaluate the physical condition of an individual who sustained an injury outside of the workplace. Pain Medicine Experts focus on the evaluation, treatment and prevention of pain. Conditions that pain medicine experts treat include chronic pain, arthritis, back and neck pain, fibromyalgia, neuropathic pain, and headaches.

One of the most common conditions treated by pain medicine experts is Complex Regional Pain Syndrome (CRPS), which is a condition that usually affects one limb, most often occurring after an injury. It is characterized by excessive or prolonged pain and changes in temperature, swelling and skin color in the affected area. CRPS is not easily identifiable, which makes it necessary to have a pain medicine expert evaluate any individual who believes he or she may suffer from the condition.

California Medical Evaluators has over 150 medical experts in all specialties available for IMEs and Expert Witness Testimony throughout the state of California. Dr. Joseph Sclafani and Dr. Mikiko Murakami are two of CMEs newest Pain Medicine Experts in the San Francisco Bay Area. Both are highly experienced with all types of spine, nerve, joint and muscle pain, including CRPS, cervical radiculopathy, rotator cuff tendonitis, low back issues, and peripheral neuropathy such as carpal tunnel syndrome.

For more information about California Medical Evaluators or to request a pain medicine expert, visit calmedeval.com.

About California Medical Evaluators

California Medical Evaluators (CME) is a leading provider of Med-Legal Practice Management services to physicians who perform Qualified Medical Examinations (QMEs), Independent Medical Examinations (IMEs) and medical expert witness engagements. CMEs broad network of qualified physician experts perform over 5,000 medical-legal examinations annually. Founded in 2010 by physicians, CME has become a leader in QME practice management, while also providing IME services, fitness for duty evaluations, and disability evaluations for the legal and insurance industries. More information about CME can be found at CalMedEval.com or by calling (888)-853-7944.

Read the rest here:

California Medical Evaluators Grows its Network of Pain Medicine Experts in the San Francisco Bay Area - Business Wire

Incidence of vincristine-induced neuropathy does not appear to be associated with nutritional deficiencies, according to research published in Pediatric Hematology and Oncology.

Vincristine, a vinca alkaloid chemotherapy drug, is commonly used in the treatment of childhood acute lymphoblastic leukemia (ALL) but can lead to chemotherapy-induced peripheral neuropathy, an important dose-limiting toxicity. However, little research has been conducted in patients with possible concomitant nutritional deficiencies.

Therefore, researchers conducted a prospective observational study over a period of 2 years at a childrens hospital in India. They evaluated 30 children with newly diagnosed ALL, 28 (93.3%) of whom had B-cell ALL and 2 (6.7%) of whom had T-cell ALL. Vitamin B12, folate, and serum ferritin levels were measured for all patients.

Over 4 weeks of observation, clinical peripheral neuropathy developed in 12 patients. Autonomic nervous system involvement was the most common, but involvement of the sensory and motor systems occurred as well. Electrophysiologic testing found that 15 patients (50%) had neuropathy.

Undernutrition, defined using criteria from the World Health Organization, was identified in 14 patients (46.7%). No difference was found in incidence of vincristine-induced neuropathy between patients with undernutrition (7 patients) and patients without undernutrition (8 patients). Additionally, the researchers found no correlation between presence of undernutrition and development of neuropathy (P =1.0). Levels of vitamin B12, folate, and serum ferritin were similar in children with and without neuropathy.

The researchers concluded that although optimal nerve function is dependent on a constant supply of macronutrients and micronutrients, nutritional deficiencies may not influence development of neuropathy in Indian children with ALL. However, they acknowledged that their study had some limitations, such as the inability to measure expression of CYP3A5 (an enzyme responsible for vincristine metabolism) and serum albumin and the use of ferritin to assess iron deficiency. They noted that further research is warranted to evaluate the role of micronutrient deficiencies in the development of vincristine-induced peripheral neuropathy in childhood ALL.

Reference

Dudeja S, Gupta S, Sharma S, et al. Incidence of vincristine induced neurotoxicity in children with acute lymphoblastic leukemia and its correlation with nutritional deficiencies [published online September 13, 2019]. Pediatr Hematol Oncol.

This article originally appeared on Hematology Advisor

Go here to see the original:

No Link Between Nutritional Deficiencies, Vincristine-Induced Neuropathy in Pediatric Acute Lymphoblastic Leukemia - Cancer Therapy Advisor

SAN FRANCISCO Aspirin does not appear to reduce the risk of nonarteritic ischemic optic neuropathy development in men, according to data presented at the 2019 American Academy of Ophthalmology Meeting in San Francisco, CA.

Using multivariate Cox regression models, the researchers sought to determine the relationship between certain factors (ie, age, race, BMI, diabetes, smoking status, Charlson comorbidity index, hypertension, peripheral vascular disease, stroke, myocardial infarction, ischemic heart disease; aspirin, statin, warfarin, clopidogrel, sildenafil use) and a new diagnosis of nonarteritic ischemic optic neuropathy using data from the California Mens Health Study.

Results showed that among 45,281 participants who completed surveys between 2002 and 2006, 130 individuals developed nonarteritic ischemic optic neuropathy between 2002 and 2015. Factors that were associated with a new diagnosis of nonarteritic ischemic optic neuropathy included age (>60 years; hazard ratio [HR] 3.74; 95% CI 1.50 to 9.31) and long-term use of aspirin (HR 1.68; 95% CI 1.09 to 2.61).

Aspirin did not protect against a first episode of [nonarteritic ischemic optic neuropathy], the researchers concluded, adding that Aspirin users had a higher incidence of [nonarteritic ischemic optic neuropathy], most likely due to unaccounted-for confounders.

Reference

Modjtahedi, B S, et al. The Relationship Between Aspirin Use and NAION in Men. Poster number: PO252. The American Academy of Ophthalmology Meeting; October 12-15 2019.

More here:

Does Aspirin Protect Against Nonarteritic Ischemic Optic Neuropathy Development in Men? - Monthly Prescribing Reference

Declines in global health status and quality of life, physical functioning, fatigue, and pain begin to appear 2 to 3 months before progression of the underlying malignant disease, multiple myeloma researchers said in a new study.

Whereas previous studies have focused on response rate, the quality of the response, progression-free survival (PFS), and overall survival (OS), increased attention is being paid to QOL issues, as patients live longer and there is a greater emphasis placed on shared decision making and a greater focus being placed on QOL data, noted the authors.

This median age of the 90 patients with relapsed/refractory MM in this study was 67 years; 41% were stage I, 33% were stage II, and 26% were stage III.

Researchers found significant impairment in health-related QOL, physical, role, and social functioning and several other dimensions, as well as more pain and fatigue, compared with the general population. Induction therapy resulted in significant improvement of pain and worsening of neuropathy, with no significant change in other categories. During maintenance treatment, health-related QOL, physical functioning, and pain improved, but neuropathy did not.

Time to deterioration (10 or more score points) of health-related QOL, physical functioning, pain, and neuropathy was distinctly shorter than time to progression. Health-related QOL and physical functioning at baseline correlated with OS.

Previous studies have shown that physicians often underestimate the impact of cancer-associated symptoms such as nausea, fatigue, or pain on patients well-being, and they presume that PFS and good QOL go hand-in-hand; that is, that as long as patients maintain their response without progressing, that they are enjoying a good QoL.

That is not supported by the evidence in this study, the researchers said, which showed that global health-status/QOL, physical functioning, fatigue, and pain begin to deteriorate 2 to 3 months before progression of the underlying malignant disease.

However, better health-related QOL was associated with increased PFS, and both higher health-related QOL and physical functioning were associated with prolonged survival. Patient-reported outcome assessments are vital for understanding "individual needs and impairments, for prognostication, and for elucidating the impact of therapy on the various dimensions of QOL," the authors said.

Reference

Ludwig H, Pnisch W, Knop S, et al.Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population [published online September 26, 2019].Leuk. Lymphoma. doi: 10.1080/10428194.2019.1666381.

The rest is here:

Quality of Life Declines for Patients With Relapsed or Refractory MM Before Progression Appears - AJMC.com Managed Markets Network

Global Cardiac Autonomic Neuropathy Treatment Market is a complete research study which portrays the present Cardiac Autonomic Neuropathy Treatment industry situations. Our latest study will provide the readers a complete knowledge about the past, present, and futuristic Cardiac Autonomic Neuropathy Treatment market aspects. In the beginning, elemental information stating the basic overview, product type, applications and Cardiac Autonomic Neuropathy Treatment development status is presented in this report. The key Cardiac Autonomic Neuropathy Treatment market trends which have led to the development of Cardiac Autonomic Neuropathy Treatment will drive useful market insights.

The key market factors which will influence the growth of Cardiac Autonomic Neuropathy Treatment industry like market share, key geographical regions, major key vendors are studied in-depth in this report. All the major Cardiac Autonomic Neuropathy Treatment regions and their contribution to the global market share are analyzed comprehensively. This report also studies the growth opportunities and the limiting factors of Cardiac Autonomic Neuropathy Treatment market. A detailed description related to supply chain structure, Cardiac Autonomic Neuropathy Treatment market size, consumer volume, and import/export scenario has been covered in this report. Analysis of major Cardiac Autonomic Neuropathy Treatment players, their company profile, market volume, Cardiac Autonomic Neuropathy Treatment production capacity, competitive landscape study will provide a complete picture of Cardiac Autonomic Neuropathy Treatment industry.

Request For Sample Report Before Buying (Use Corporate eMail ID to Get Higher Priority):https://market.us/report/cardiac-autonomic-neuropathy-treatment-market/request-sample

Major dominant companies are listed below:

PfizerRoche HoldingNovartisAmgenPrivi PharmaSilverline ChemicalsAnthem BiopharmaPraxis Pharmaceutical

Product Categories:

Solid OralInjectable

Product End-use Applications:

HospitalsCardiac CentersAmbulatory Surgical Centers

Top Geographical regions:

North America (US, Canada, and Mexico) Europe (Germany, France, UK, Russia, Italy, Spain, and Rest of Europe) Asia-Pacific (China, Japan, Korea, India, and Rest of Asia) Latin America (Brazil, Argentina, and the Rest of Latin America) The Middle East and Africa (GCC, South Africa, Israel, and Rest of MEA)

Inquire Before Buying Report (Use Corporate email ID to Get Higher Priority): https://market.us/report/cardiac-autonomic-neuropathy-treatment-market/ inquiry

Cardiac Autonomic Neuropathy Treatment market research provides answers to the following key questions:

-What will be the market size and the growth rate from 2019 to 2029?

-What are the key factors driving and retaining factors of Global Cardiac Autonomic Neuropathy Treatment Market?

-Who are the key market vendors and what are their strategies in the Global Cardiac Autonomic Neuropathy Treatment Market?

-What are the trending factors influencing the Cardiac Autonomic Neuropathy Treatment market shares in the Asia Pacific, North America, Latin America, Europe and Middle East and Africa?

-What trends, challenges, and barriers are influencing Cardiac Autonomic Neuropathy Treatment growth?

-What are the market opportunities and threats faced by the vendors in the Global Cardiac Autonomic Neuropathy Treatment Market?

Hence Cardiac Autonomic Neuropathy Treatment report evaluates all the crucial factors including the key players analysis, their business tactics and Cardiac Autonomic Neuropathy Treatment development expected during the forecast period. The analysis of top companies, their Cardiac Autonomic Neuropathy Treatment market revenue, consumer volume, emerging and existing Cardiac Autonomic Neuropathy Treatment market segments will help all the market players.

View Detailed Report Here:https://market.us/report/cardiac-autonomic-neuropathy-treatment-market/

Contact Us:Mr. Benni JohnsonMarket.us (Powered By Prudour Pvt. Ltd.)Tel: +1 718 618 4351.Email: [emailprotected]

Refer our Trending Reports:

Cold Box Casting Resin Market Forecast to 2029 | Profiling Global Players HA-International, Vesuvius Group and ASK ChemicalsThe Benefits Of Global Direct Drive Spindle Market to Rear Excessive Growth During 2029

Visit link:

Global Cardiac Autonomic Neuropathy Treatment Market Top Insights 2020:-Novartis, Pfizer and Roche Holding - Tech News Today

With a major research university right in our backyard, a strong military presence and innovative companies throughout the metro region, theres often a plethora of interesting science and technology news to be found in Southern Arizona. Heres a breakdown of the most interesting recent developments.

Smartphones and Depression. While a growing body of evidence connects technology addiction with depression and loneliness, its been unclear which leads to the other. Does constant smartphone usage make people depressed, or are depressed people more likely to spend time on their smartphones? A new study from researchers at the University of Arizonas College of Social and Behavioral Sciences found that smartphone dependency predicts higher reports of depressive symptoms and loneliness, rather than the other way around. The study examined 346 people aged 17-20 and the links between their smartphone engagement and psychological well-being. According to researcher Matthew Lapierre, the main takeaway from the study is smartphone dependency directly predicts later depressive symptoms. The study recommended health practitioners communicate with patients and parents about the links between smartphone use and psychological well-being.

Tech Jobs in Arizona. The Arizona Technology Council recently announced Arizonas tech sector is growing at a rate 40 percent faster than the U.S. overall. The announcement was in the Arizona Technology Councils quarterly impact report, which found the state has added 2,600 technology jobs since the beginning of the year. This brings the total number of technology-related jobs in Arizona to more than 180,000. These jobs tend to be high-paying, more than average Arizona wages, with an average annual salary of more than $80,000. Even more, these types of jobs are seeing consistent wage growth. This means Arizonas technology wages are now 20 percent higher than the national average. And although these STEM-related jobs generally require higher-education, nearly 30 percent of these STEM post-secondary graduates are staying in the state to work.

Quantum Sounds. A new paper published by researchers at the University of Arizonas Department of Materials Science and Engineering shows the possibility for acoustic waves to work in quantum information processing. In traditional computing, information is stored in binary (with a value of either 0 or 1), but in quantum computing, information can be stored in both positions at once (described as a superposition). While this massively increases the potential for computing, these entangled quantum bit states, or qubits, usually last less than a second before collapsing. Units of light are used in quantum mechanics for data processing, but the UA researchers are taking this a step further. In their paper The sound of Bell states they demonstrated for the first time that classical nonseparability can be applied to acoustic waves, not just light waves. Light lasers and single photons are part of the field photonics, but soundwaves fall under the umbrella of phononics, or the study of phonons, said Pierre Deymier, MSE department head. In addition to being stable, classically entangled acoustic waves are easy to interact with and manipulate.

Treating Chemotherapy Pain without Opioids. Researchers at UA Health Sciences are researching an effective, non-opioid treatment for neuropathic pain caused by chemotherapy. While chemotherapy remains one of the key treatments for cancer, it often causes damaging side effects, such as chemotherapy-induced peripheral neuropathy (CIPN), which is defined as damage to the nerves outside the brain and spinal cord, and is detected in 64 percent of cancer patients. In an attempt to create a less addictive treatment for CIPN, researchers are developing potent and selective T-type calcium channel antagonists. While initial results in pain management on rodent models have been promising, the research is still in its very early stages. According to professor of pharmacology Rajesh Khanna, this is the first step in developing non-opioid pain treatments for CIPN. This research is partially funded by a $340,000 grant from the National Institutes of Health as part of the Helping to End Addiction Long-Term initiative.

Link:

Connecting smartphones to depression | News - Inside Tucson Business

A research report on Peripheral Neuropathy Treatment Market 2019 Industry Research Report is being published by researchunt.com. This is a key document as far as the clients and industries are concerned to not only understand the competitive market status that exists currently but also what future holds for it in the upcoming period, i.e., between 2018 and 2025. It has taken the previous market status of 2013 2018 to project the future status. The report has categorized in terms of region, type, key industries, and application.

A sample of report copy could be downloaded by visiting the site:marketreports.co/global-peripheral-neuropathy-treatment-market-size-status-and-forecast-2019-2025/103336/#Free-Sample-Report

Global Peripheral Neuropathy Treatment revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2018-2023.

Major Geographical Regions

The study report on Global Peripheral Neuropathy TreatmentMarket 2018 would cover every big geographical, as well as, sub-regions throughout the world. The report has focused on market size, value, product sales and opportunities for growth in these regions. The market study has analyzed the competitive trend apart from offering valuable insights to clients and industries. These data will undoubtedly help them to plan their strategy so that they could not only expand but also penetrate into a market.

The researchers have analyzed the competitive advantages of those involved in the industries or in the Peripheral Neuropathy Treatmentindustry. While historical years were taken as 2013 2017, the base year for the study was 2017. Similarly, the report has given its projection for the year 2018 apart from the outlook for years 2018 2025.

Key Players and Type

Like any other research material, the report has covered key geographical regions such as Europe, Japan, United States, India, Southeast Asia and Europe. Researchers have given their opinion or insights of value, product sales, and industry share besides availability opportunities to expand in those regions. As far as the sub-regions, North America, Canada, Medico, Australia, Asia-Pacific, India, South Korea, China, Singapore, Indonesia, Japan, Rest of Asia-Pacific, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, Russia, Central & South America, Middle East & Africa are included.

Major players in the report included are :

Types covered in thePeripheral Neuropathy Treatmentindustryare :

Applications covered in the report are :

Report Aims

The objective of the researchers is to find out sales, value, and status of the Peripheral Neuropathy Treatmentindustry at the international levels. While the status covers the years of 2013 17, the forecast is for the period 2018 25 that will enable market players to not only plan but also execute strategies based on the market needs.

Read Detailed Index of full Research Study at @marketreports.co/global-peripheral-neuropathy-treatment-market-size-status-and-forecast-2019-2025/103336/

The study wanted to focus on key manufacturers, competitive landscape, and SWOT analysis for Peripheral Neuropathy Treatmentindustry. Apart from looking into the geographical regions, the report concentrated on key trends and segments that are either driving or preventing the growth of the industry. Researchers have also focused on individual growth trend besides their contribution to the overall market.

There are 15 Chapters to display the GlobalPeripheral Neuropathy Treatmentmarket.

Sections 1. Industry Synopsis of Global Peripheral Neuropathy Treatment Market.

Sections 2. Peripheral Neuropathy Treatment Market Organization Producers analysis and Profiles.

Sections 3. Peripheral Neuropathy Treatment Market Size by Type and Application.

Sections 4. Global Peripheral Neuropathy Treatment Market 2018 Analysis by key traders.

Sections 5. Europe Peripheral Neuropathy Treatment Industry Report Development Status and Outlook.

Sections 6. Japan Peripheral Neuropathy Treatment Industry Report Development Status and Outlook.

Sections 7. Development Status and improvements of Peripheral Neuropathy Treatment Market in the United States.

Sections 8. Southeast Asia Peripheral Neuropathy Treatment Market Improvement Status and Outlook.

Sections 9. China Peripheral Neuropathy Treatment Market Report Development Status and Outlook.

Sections 10. India Peripheral Neuropathy Treatment Market Development Status and Outlook.

Sections 11. Peripheral Neuropathy Treatment Market Figure by Aoplications, areas, and Sorts (2018-2023)

Sections 12. Peripheral Neuropathy Treatment Market Factors Analysis.

Sections 13. Peripheral Neuropathy Treatment Market Dynamics.

Sections 14. Research Findings and Conclusions of Peripheral Neuropathy Treatment Market.

Sections 15. Appendix.

Browse Detailed TOC, Tables, Figures, Charts And Companies Mentioned In Peripheral Neuropathy Treatment Market Research Report At@marketreports.co/global-peripheral-neuropathy-treatment-market-size-status-and-forecast-2019-2025/103336/#Buying-Enquiry

View original post here:

Peripheral Neuropathy Treatment Market 2025: Topmost manufacturers With Size, Regions, Types, Major Drivers, Profits - TheFinanceTime